| Bioactivity | Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (Ki of 0.56-2.1 μM for NMDA receptor; IC50s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects[1]. | |||||||||
| Target | NMDA receptor | |||||||||
| Invitro | Cell Line: | |||||||||
| In Vivo | Lanicemine produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects[1].Lanicemine (3, 10 or 30 mg/kg; intraperitoneal) not only engages brain circuits involved in the generation of gamma- electroencephalography (EEG), but also influences these networks independent of the broader systems-level disruptions typical of ketamine[1]. Animal Model: | |||||||||
| Name | Lanicemine | |||||||||
| CAS | 153322-05-5 | |||||||||
| Formula | C13H14N2 | |||||||||
| Molar Mass | 198.26 | |||||||||
| Appearance | Liquid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Sanacora G, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacywith minimal psychotomimetic adverse effects. Mol Psychiatry. 2014 Sep;19(9):978-85. |